Google+ Facebook Twitter Twitter

New monotest system launched

Launch Diagnostics is pleased to introduce the new VIrClia monotest system, an indirect chemiluminescent immunoassay for the detection of antibodies against infectious diseases in human serum or plasma samples.

Each monotest contains wells for automatic sample addition plus the reagents necessary to perform the assay.  

Assays are automatically processed on the VirClia instrument with VirClia processing and interpretation software. 

The easy-to-use system supports bar code identification, use of primary sample tubes within the instrument racks and is completely versatile, enabling the custom set up of different assays in a single run. The Vircell portfolio includes infectious disease ELISAs and IFAs.

Related Articles

Stopping Parkinson's disease

It may be possible to stop the progression of Parkinson’s disease with a drug usually used for type 2 diabetes.

Blood test to detect brain metastases

Cancer researchers are now closer to creating a blood test that can identify breast cancer patients who are at increased risk of developing brain metastasis, and can monitor disease progression and response to therapy in real time.

The wearable device that bites

Martin Mintchev tells Sarah Campbell about the e-mosquito – which has been in development for 10 years and is hoped to help people monitor their type 1 diabetes.

Can tumour characteristics predict treatment success?

The molecular make-up of lung tumours could help identify patients who might benefit from immunotherapy treatment up front, a US study has found.